Additionally, DC-based immunotherapy combined with anti–CTLA-4 treatment has been shown to be more effective than the use of these agents alone in two small trials, showing a best ORR of 38% in melanoma patients [162,163]. The gene discussed is CTLA4; the disease is melanoma.